Get an early preview of the new iBridge Network

Access new technology search features and an extended innovation database with new transformative technologies
fed into the platform by our member Academic Institutions, Research Labs, SMEs, Startups


Metabolically Stable, Non-Nephrotoxic Puromycin Analogs as Oncology and Anti-infective Therapeutics

Medical University of South Carolina
posted on 03/28/2011

The synthesized compounds are novel analogs of Puromycin that have maintained the same antimicrobial and antitumor activities of the naturally occurring form, but block the formation of toxic by-products. These new analogs may provide promising chemotherapeutic agents that have the same effectiveness of Puromycin without the nephrotoxicity. In preliminary studies, the target compound showed cytotoxicity in breast cancer and leukemia cell lines at levels comparable to Puromycin.




Puromycin is a long-known antibiotic agent derived from the bacteria Streptomyces alboniger. By mimicking the 3'-end of aminoacyl-tRNA, Puromycin inhibits amino acid synthesis during translation. While Puromycin has clear scope for use as an antitumor agent, its metabolic conversion to Puromycin aminonucleoside (PAN) has potent, nephrotoxic side effects that have limited its potential for clinical use. To fully exploit Puromycin as an anticancer agent, it is necessary to develop a metabolically stable analog that retains the same antimicrobial and antitumor properties as the original compound, but lacks the nephrotoxicity.



Decreased nephrotoxicity with comparable cytotoxicity


Key Words: Cancer, antitumor agent, antibacterial, Puromycin


Publications: Gilbert, Carrie LK, et al. "Synthesis of l, l-puromycin." Tetrahedron 61.35 (2005): 8339-8344.


Inventors:                                  G. Gumina, R. White

Patent Status:                         US Patent 7,897,759

MUSC-FRD Technology ID:    P0709


Innovation Details

File Number: P0709 

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact Marketing / Licensing Officer at Medical University of South Carolina for more information.

Request more info via email request more info

Principal Investigator:

Giuseppe Gumina Giuseppe Gumina

Innovations (2)


Roger White Roger White

Innovations (1)

Case Manager:

Marketing / Licensing Officer Marketing / Licensing Officer

Innovations (62)

Download Technology Brief (PDF)

Followed By

Follow this innovation

No one is following this innovation.

Related Tags

Find more innovations

February 11, 2009

13,715 members 17,882 innovations 176 organizations


David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...